Get the Stockscreener App
3.17
0.94%
-0.03
Evaxion A S Adr stock is traded at $3.17, with a volume of 9,806.
It is down -0.94% in the last 24 hours and down -16.36% over the past month.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
See More
Previous Close:
$3.20
Open:
$3.19
24h Volume:
9,806
Relative Volume:
0.33
Market Cap:
$26.44M
Revenue:
$7.50M
Net Income/Loss:
$-9.85M
P/E Ratio:
-2.2929
EPS:
-1.3825
Net Cash Flow:
$-24.56M
1W Performance:
-7.04%
1M Performance:
-16.36%
6M Performance:
-37.60%
1Y Performance:
+22.87%
1-Day Range:
$3.12
$3.19
1-Week Range:
$3.12
$3.60
52-Week Range:
$2.45
$12.15
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
3.17 | 26.44M | 7.50M | -9.85M | -24.56M | -1.3825 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Maxim Group | Buy |
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion A S Adr Stock (EVAX) Latest News
European ADRs Rose As Biopharma Names Led The Pack - Finimize
US-Traded European Stocks Slipped As Arm And ArcelorMittal Fell - Finimize
Evaxion A/S Sponsored ADR Actuals & Estimates (NASDAQ:EVAX) - TradingView
European ADRs Edged Higher As Biotech Led Friday’s Moves - Finimize
Evaxion receives Prix Galien UK Award for Best digital health solution - Finansavisen
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - Finansavisen
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia - GlobeNewswire Inc.
European ADRs Started The Week In The Green - Finimize
European ADRs Edged Higher In US Trading - Finimize
EVAXEvaxion A/S ADR Options - Finviz
Evaxion Biotech Signals Strong R&D Momentum Amid Cash Constraints - TipRanks
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - Finansavisen
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - Finansavisen
Evaxion concludes Annual General Meeting - Finansavisen
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 - Finansavisen
Endesa S.A. – Unsponsored ADR (OTCMKTS:ELEZY) Given Average Rating of “Strong Sell” by Brokerages - Defense World
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Europe’s US-Listed ADRs Rose, Led By Solar And Biotech - Finimize
European ADRs Rose, While Biotech Names Did The Heavy Lifting - Finimize
Evaxion Biotech Earnings Call Highlights AI and Runway - TipRanks
Evaxion A/S (NASDAQ:EVAX) Receives Buy Rating from HC Wainwright - Defense World
Evaxion A/S (NASDAQ:EVAX) Price Target Cut to $9.00 by Analysts at Lake Street Capital - Defense World
Evaxion Earnings Report: Q4 Overview - Sahm
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 20.9% in February - Defense World
Evaxion Biotech's Earnings: A Preview - Sahm
European ADRs Slip Slightly As Winners And Losers Split - Finimize
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
European ADRs Edge Higher Despite Mixed Stock Moves - Finimize
Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Target Price at $12.33 - Defense World
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
European Biotech Stocks Outperformed As Broader Market Dipped - Finimize
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Evaxion Stock Climbs Amid Biotech Surge - StocksToTrade
Evaxion Biotech A/S Announces Change in American Depositary Shares Ratio to Enhance Liquidity - nasdaq.com
Evaxion A/S (EVAX) Stock Forecast and Price Target 2026 - MarketBeat
Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today? - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab - Nasdaq
Evaxion Biotech (EVAX) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
What is the current Price Target and Forecast for Evaxion A/SSponsored ADR (EVAX) - Zacks Investment Research
Top movers in Friday's pre-market session - ChartMill
Evaxion A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):